Genetic risk for restenosis after coronary balloon angioplasty

Atherosclerosis

Volumn 174, Issue 1, 2004, Pages 181-187

  Horibe, Hideki ^a   Yamada, Yoshiji ^b,c   Ichihara, Sahoko ^d   Watarai, Masato ^a   Yanase, Masanobu ^a   Takemoto, Kenji ^a   Shimizu, Seiji ^a   Izawa, Hideo ^d   Takatsu, Fumimaro ^a   Yokota, Mitsuhiro ^d  

^a ANJO KOSEI HOSPITAL   (Japan)

^b GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

^c MIE UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angioplasty; Coronary artery disease; Genetics; Polymorphism; Restenosis

Indexed keywords

OXIDOREDUCTASE; PRIMER DNA; PROTEIN P22; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ADJUSTMENT; ADULT; AGE; AGED; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CLINICAL FEATURE; COLORIMETRY; CONTROLLED STUDY; CORONARY ARTERY SURGERY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FLUORESCENCE; GENE; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERURICEMIA; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PARAOXONASE 1 GENE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RESTENOSIS; RISK FACTOR; SMOKING; STATISTICAL SIGNIFICANCE; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGE DISTRIBUTION; AGED; ANGIOPLASTY, BALLOON; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL ANALYSIS;

EID: 2342649958     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2004.01.022     Document Type: Article

References (26)

1. McBride W., Lange R.A., Hillis L.D. Restenosis after successful coronary angioplasty. pathophysiology and prevention. N. Engl. J. Med. 318:1998;1734-1737
2. Serruys P.W., de Jaegere P., Kiemeneij F., et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N. Engl. J. Med. 331:1994;489-495
3. Hirshfeld J.W. Jr., Schwartz J.S., Jugo R., et al. Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. The M-HEART Investigators. J. Am. Coll. Cardiol. 18:1991;647-656
4. Weintraub W.S., Kosinski A.S., Brown C.L. 3rd, King S.B. 3rd Can restenosis after coronary angioplasty be predicted from clinical variables. J. Am. Coll. Cardiol. 21:1993;6-14
5. Stein B., Weintraub W.S., Gebhart S.S.P., et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation. 91:1995;979-989
6. Violaris A.G., Melkert R., Serruys P.W. Long-term luminal renarrowing after successful elective coronary angioplasty of total occlusions: a quantitative angiographic analysis. Circulation. 91:1995;2140-2150
7. Mintz G.S., Popma J.J., Pichard A.D., et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 94:1996;35-43
8. Völzke H., Hertwig S., Rettig R., Motz W. The angiotensinogen gene 235T variant is associated with an increased risk of restenosis after percutaneous transluminal coronary angioplasty. Clin. Sci. 99:2000;19-25
9. van Bockxmeer F.M., Mamotte C.D.S., Gibbons F.R., Taylor R.R. Apolipoprotein ε4 homozygosity-a determinant of restenosis after coronary angioplasty. Atherosclerosis. 110:1994;195-202
10. Humphries S., Bauters C., Meirhaeghe A., et al. The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis. Eur. Heart J. 23:2002;721-725
11. Rauchhaus M., Gross M., Schulz S., et al. The E-selectin SER128ARG gene polymorphism and restenosis after successful coronary angioplasty. Int. J. Cardiol. 83:2002;249-257
12. Yamada Y., Izawa H., Ichihara S., et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N. Engl. J. Med. 347:2002;1916-1923
13. Serrato M., Marian A.J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J. Clin. Invest. 96:1995;3005-3008
14. Griendling K.K., Sorescu D., Ushio-Fukai M. NAD(P)H oxidase. Role in cardiovascular biology and disease. Circ. Res. 86:2000;494-501
15. Azumi H., Inoue N., Takeshita S., et al. Expression of NADH/NADPH oxidase p22 phox in human coronary arteries. Circulation. 100:1999;1494-1498
16. Inoue N., Kawashima S., Kanazawa K., et al. Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation. 97:1998;135-137
17. Guzik T.J., West N.E.J., Black E., et al. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22 phox gene on vascular superoxide production in atherosclerosis. Circulation. 102:2000;1744-1747
18. Dittman W.A., Majerus P.W. Structure and function of thrombomodulin: a novel anticoagulant. Blood. 75:1990;329-336
19. Esmon C.T. Thrombomodulin as a model of molecular mechanism that modulates protease specificity and function at the vessel surface. FASEB J. 9:1995;946-955
20. Wu K.K., Aleksic N., Ahn C., et al. Thrombomodulin Ala455Val polymorphism and risk of coronary heart disease. Circulation. 103:2001;1386-1389
21. Mackness M.I., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286:1991;152-154
22. Humbert R., Adler D.A., Disteche C.M., et al. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3:1993;73-76
23. Sanghera D.K., Saha N., Aston C.E., Kamboh M.I. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 17:1997;1067-1073
24. Baier L.J., Sacchettini J.C., Knowler W.C., et al. An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. J. Clin. Invest. 95:1995;1281-1287
25. Carlsson M., Orho-Melander O., Hedenbro J., Almgren P., Groop L.C. The T54 allele of the intestinal fatty acid-binding protein 2 is associated with a parental history of stroke. J. Clin. Endocrinol. Metab. 85:2000;2801-2804
26. Koh K.K. Effects of estrogen on the vascular wall: vasomotor function and inflammation. Cardiovasc. Res. 55:2002;714-726